Axa’s Cytokinetics CYTK Stock Holding History

Axa’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-119,873	Closed	-$4.82M	–	1138
2025 Q1	$4.82M	Sell	119,873 -151	-0.1%	-$6.94K	0.02%	551
2024 Q4	$5.65M	Sell	120,024 -190	-0.2%	-$9.87K	0.02%	509
2024 Q3	$6.35M	Buy	120,214 +36	+0%	+$2.01K	0.02%	480
2024 Q2	$6.51M	Buy	120,178 +67	+0.1%	+$4.04K	0.02%	476
2024 Q1	$8.42M	Buy	120,111 +34	+0%	+$2.63K	0.03%	440
2023 Q4	$10M	Buy	+120,077	New	+$4.35M	0.03%	391

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Axa's CYTK Position: Q2 2025 in Review

Axa sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 119,873 shares — an estimated $4.82M sold.

Axa first reported a position in CYTK in Q4 2023 and held it in 6 quarters. The position peaked at $10M in Q4 2023. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

Axa reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
Axa sold 119,873 Cytokinetics shares in Q2 2025, an estimated $4.82M.
Axa first reported a position in Cytokinetics in Q4 2023 and held it in 6 quarters.
Axa's Cytokinetics position peaked at $10M in Q4 2023.
311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on Axa's 13F filing for Q2 2025, filed 14 Aug 2025.